Johnson & Johnson (NYSE:JNJ) – Stock analysts at Jefferies Group boosted their FY2018 earnings estimates for Johnson & Johnson in a research note issued to investors on Tuesday. Jefferies Group analyst J. Holford now expects that the company will earn $8.31 per share for the year, up from their prior estimate of $8.17. Jefferies Group currently has a “Buy” rating and a $160.00 target price on the stock. Jefferies Group also issued estimates for Johnson & Johnson’s FY2022 earnings at $11.58 EPS.

A number of other equities analysts have also recently issued reports on the stock. Goldman Sachs Group cut shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and raised their target price for the stock from $125.00 to $130.00 in a report on Wednesday, September 20th. Vetr raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 target price on the stock in a report on Monday, October 30th. Credit Suisse Group set a $154.00 target price on shares of Johnson & Johnson and gave the stock an “outperform” rating in a report on Thursday, October 19th. BMO Capital Markets raised their target price on shares of Johnson & Johnson to $161.00 and gave the stock an “outperform” rating in a report on Tuesday, December 12th. Finally, Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $145.94.

Shares of Johnson & Johnson (NYSE:JNJ) traded up $0.12 during midday trading on Wednesday, reaching $146.98. 10,618,239 shares of the company’s stock were exchanged, compared to its average volume of 6,299,060. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 1 year low of $110.76 and a 1 year high of $148.06. The company has a market capitalization of $394,860.00, a PE ratio of 25.52, a P/E/G ratio of 2.75 and a beta of 0.80.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping the Zacks’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The business had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. During the same period last year, the firm earned $1.68 earnings per share. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be issued a dividend of $0.84 per share. The ex-dividend date is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.29%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Stillwater Capital Advisors LLC increased its stake in shares of Johnson & Johnson by 1.4% during the second quarter. Stillwater Capital Advisors LLC now owns 89,136 shares of the company’s stock valued at $11,792,000 after acquiring an additional 1,269 shares during the period. Carlton Hofferkamp & Jenks Wealth Management LLC increased its stake in shares of Johnson & Johnson by 3.6% during the second quarter. Carlton Hofferkamp & Jenks Wealth Management LLC now owns 18,987 shares of the company’s stock valued at $2,511,000 after acquiring an additional 652 shares during the period. Beacon Financial Group increased its stake in shares of Johnson & Johnson by 2.1% during the second quarter. Beacon Financial Group now owns 87,012 shares of the company’s stock valued at $11,541,000 after acquiring an additional 1,814 shares during the period. First Command Bank increased its stake in shares of Johnson & Johnson by 4.4% during the second quarter. First Command Bank now owns 11,163 shares of the company’s stock valued at $1,476,000 after acquiring an additional 472 shares during the period. Finally, Stock Yards Bank & Trust Co. increased its stake in shares of Johnson & Johnson by 5.7% during the second quarter. Stock Yards Bank & Trust Co. now owns 135,744 shares of the company’s stock valued at $17,957,000 after acquiring an additional 7,347 shares during the period. 65.71% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Brokers Set Expectations for Johnson & Johnson’s FY2018 Earnings (JNJ)” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/01/17/brokers-set-expectations-for-johnson-johnsons-fy2018-earnings-jnj.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.